Brentuximab vedotin monotherapy is an effective treatment in a frail pediatric patient with Down syndrome and classical Hodgkin lymphoma

被引：1
|
作者：
Vonasek, Julia [1 ]
Edslev, Pernille Wendtland [1 ]
d'Amore, Francesco [2 ]
Hasle, Henrik [1 ]
机构：
[1] Aarhus Univ Hosp, Dept Pediat & Adolescent Hlth, Aarhus, Denmark
[2] Aarhus Univ Hosp, Dept Hematol, Aarhus, Denmark
来源：
PEDIATRIC BLOOD & CANCER | 2020年 / 67卷 / 02期
关键词：
D O I：
10.1002/pbc.28082
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma
    Lee, Hun Ju
    Ramchandren, Rod
    Friedman, Judah
    Melear, Jason
    Flinn, Ian W.
    Burke, John M.
    Linhares, Yuliya
    Gonzales, Paul
    Peterson, Matthew
    Raval, Mihir
    Chintapatla, Rangaswamy
    Feldman, Tatyana A.
    Yimer, Habte
    Islas-Ohlmayer, Miguel
    Patel, Ameet
    Metheny, Leland
    Dean, Asad
    Rana, Vishal
    Gandhi, Mitul D.
    Renshaw, John
    Ho, Linda
    Fanale, Michelle A.
    Guo, Wenchuan
    Yasenchak, Christopher A.
    BLOOD, 2025, 145 (03) : 290 - 299
  • [42] Severe peripheral motor neuropathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin
    Pastorelli, Francesca
    Derenzini, Enrico
    Plasmati, Rosaria
    Pellegrini, Cinzia
    Broccoli, Alessandro
    Casadei, Beatrice
    Argnani, Lisa
    Salvi, Fabrizio
    Pileri, Stefano
    Zinzani, Pier Luigi
    LEUKEMIA & LYMPHOMA, 2013, 54 (10) : 2318 - 2321
  • [43] POPULATION PHARMACOKINETICS OF NIVOLUMAB IN PEDIATRIC PATIENTS WITH CLASSICAL HODGKIN'S LYMPHOMA WHEN ADMINISTERED IN COMBINATION WITH BRENTUXIMAB VEDOTIN.
    Vuppala, P.
    Vezina, H.
    Maloney, M.
    Sacchi, M.
    Kieran, M.
    Roy, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 : S35 - S36
  • [44] Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes
    Cheah, C. Y.
    Chihara, D.
    Horowitz, S.
    Sevin, A.
    Oki, Y.
    Zhou, S.
    Fowler, N. H.
    Romaguera, J. E.
    Turturro, F.
    Hagemeister, F. B.
    Fayad, L. E.
    Wang, M.
    Neelapu, S. S.
    Nastoupil, L. J.
    Westin, J. R.
    Rodriguez, M. A.
    Samaniego, F.
    Anderlini, P.
    Nieto, Y.
    Fanale, M. A.
    ANNALS OF ONCOLOGY, 2016, 27 (07) : 1317 - 1323
  • [45] Severe subacute onset sensorimotor polyneuropathy associated with brentuximab vedotin treatment for refractory classical Hodgkin's lymphoma
    McNicholas, Nuala
    Hiew, Hwai Jing
    Arunachalam, Ramamurthy
    Osman, Chinar
    BMJ CASE REPORTS, 2024, 17 (11)
  • [46] Brentuximab Vedotin: A New Age in the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma
    Minich, Stephanie S.
    ANNALS OF PHARMACOTHERAPY, 2012, 46 (03) : 377 - 383
  • [47] Brentuximab vedotin in the treatment of a patient with refractory Hodgkin disease and Proteus syndrome - a case report and discussion
    Myakova, Natalia
    Smirnova, Nadezhda
    Evstratov, Dmitry
    Abugova, Yulia
    Balashov, Dmitry
    Diakonova, Yulia
    Konovalov, Dmitry
    Skvortsova, Yulia
    Maschan, Alexey
    CLINICAL CASE REPORTS, 2015, 3 (07): : 646 - 649
  • [48] Pharmacokinetics, immunogenicity, and safety of weekly dosing of brentuximab vedotin in pediatric patients with Hodgkin lymphoma
    Flerlage, Jamie E.
    Metzger, Monika L.
    Wu, Jianrong
    Panetta, John C.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (06) : 1217 - 1223
  • [49] PHARMACOKINETICS, IMMUNOGENICITY AND SAFETY OF WEEKLY DOSING OF BRENTUXIMAB VEDOTIN IN PEDIATRIC PATIENTS WITH HODGKIN LYMPHOMA
    Flerlage, J.
    Metzger, M.
    Panetta, J. C.
    HAEMATOLOGICA, 2016, 101 : 36 - 37
  • [50] Pharmacokinetics, immunogenicity, and safety of weekly dosing of brentuximab vedotin in pediatric patients with Hodgkin lymphoma
    Jamie E. Flerlage
    Monika L. Metzger
    Jianrong Wu
    John C. Panetta
    Cancer Chemotherapy and Pharmacology, 2016, 78 : 1217 - 1223
12345